HERACLES: A Phase II single-arm prospective study to assess the efficacy of Fecal Microbiota Transfer (FMT) in the treatment of steroid-refractory gastro-intestinal predominant aGVHD post allo-hsct
Previous PostMaaT Pharma Completes Third Positive DSMB Assessment Setting High Safety Standard for Human Intestinal Microbiome Whole Ecosystem-Based Therapeutics
Next PostIMM-ETG - A New European Initiative for Intestinal Microbiome Medicinal Products